PriceTargets.com logo

NASDAQ:PGEN - Precigen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.50
  • Forecasted Upside: 758.21 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.34 As of 06/30/2022 01:00 AM ET
▼ -0.02 (-1.47%)

This chart shows the closing price for PGEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Precigen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PGEN

Analyst Price Target is $11.50
▲ +758.21% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Precigen in the last 3 months. The average price target is $11.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 758.21% upside from the last price of $1.34.

This chart shows the closing price for PGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Precigen. This rating has held steady since August 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2022HC WainwrightReiterated RatingBuy$10.00Low
12/14/2021JMP SecuritiesReiterated RatingBuy$13.00Low
11/5/2021JMP SecuritiesReiterated RatingBuy$13.00Low
10/1/2021JMP SecuritiesReiterated RatingBuy$13.00Medium
8/10/2021HC WainwrightReiterated RatingBuy$10.00Low
5/11/2021HC WainwrightReiterated RatingBuyHigh
3/2/2021B. RileyBoost Price TargetBuy$10.00 ➝ $14.00High
2/25/2021Stifel NicolausInitiated CoverageBuy$13.00High
2/22/2021Wells Fargo & CompanyInitiated CoverageOverweight$14.00High
2/17/2021B. RileyInitiated CoverageBuy$10.00Medium
12/16/2020HC WainwrightBoost Price TargetBuy$8.00 ➝ $10.00High
6/24/2020HC WainwrightReiterated RatingBuy$8.00Low
6/10/2020JMP SecuritiesReiterated RatingOutperform$13.00High
5/8/2020HC WainwrightInitiated CoverageBuy$5.00Medium
8/12/2019Northland SecuritiesReiterated RatingHold$10.00Medium
8/9/2019Bank of AmericaLower Price TargetUnderperform$7.00 ➝ $6.00N/A
5/14/2019Northland SecuritiesReiterated RatingHold$7.00High
3/6/2019JMP SecuritiesReiterated RatingBuy$43.00Medium
3/1/2019Northland SecuritiesDowngradeOutperform ➝ Market PerformHigh
10/10/2018JMP SecuritiesBoost Price TargetMarket Outperform ➝ Market Outperform$42.00 ➝ $43.00Medium
7/17/2018Stifel NicolausInitiated CoverageBuy$72.00Low
7/16/2018Bank of AmericaDowngradeNeutral ➝ Underperform$12.00High
3/5/2018JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Neutral$22.00 ➝ $18.00High
3/2/2018Bank of AmericaLower Price TargetNeutral ➝ Neutral$21.00 ➝ $19.00Medium
3/2/2018Northland SecuritiesReiterated RatingBuy$17.00High
11/10/2017Northland SecuritiesReiterated RatingBuy$21.00N/A
11/10/2017Bank of AmericaLower Price TargetNeutral$25.00 ➝ $21.00N/A
11/10/2017Stifel NicolausBoost Price TargetBuy$39.00 ➝ $57.00N/A
10/6/2017Northland SecuritiesReiterated RatingBuy$27.00N/A
10/6/2017Griffin SecuritiesReiterated RatingBuy$55.00N/A
10/5/2017JMP SecuritiesReiterated RatingOutperform$42.00N/A
8/7/2017Northland SecuritiesSet Price TargetBuy$30.00Low
(Data available from 6/30/2017 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/2/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2022
  • 4 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
1/31/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/2/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/1/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/31/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/30/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Precigen logo
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Read More

Today's Range

Now: $1.34
Low: $1.30
High: $1.36

50 Day Range

MA: $1.33
Low: $1.15
High: $1.60

52 Week Range

Now: $1.34
Low: $1.12
High: $6.68

Volume

705,430 shs

Average Volume

1,496,472 shs

Market Capitalization

$278.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.43

Frequently Asked Questions

What sell-side analysts currently cover shares of Precigen?

The following sell-side analysts have issued research reports on Precigen in the last year: HC Wainwright, and JMP Securities.
View the latest analyst ratings for PGEN.

What is the current price target for Precigen?

0 Wall Street analysts have set twelve-month price targets for Precigen in the last year. Their average twelve-month price target is $11.50, suggesting a possible upside of 767.9%.
View the latest price targets for PGEN.

What is the current consensus analyst rating for Precigen?

Precigen currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PGEN will outperform the market and that investors should add to their positions of Precigen.
View the latest ratings for PGEN.

How do I contact Precigen's investor relations team?

Precigen's physical mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The biotechnology company's listed phone number is (301) 556-9900 and its investor relations email address is [email protected] The official website for Precigen is www.precigen.com. Learn More about contacing Precigen investor relations.